Evidence map›Paper›PMID 33271959›Full record

ReviewJournal of clinical medicine2020

Effectiveness of Platelet Function Analysis-Guided Aspirin and/or Clopidogrel Therapy in Preventing Secondary Stroke: A Systematic Review and Meta-Analysis.

Ann-Rong Yan, Mark Naunton, Gregory M Peterson, Israel Fernandez-Cadenas, Reza Mortazavi

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ann-Rong YanSchool of Health Sciences, Faculty of Health, University of Canberra, Canberra 2617, Australia.ORCID 0000-0003-2286-7943
Mark NauntonSchool of Health Sciences, Faculty of Health, University of Canberra, Canberra 2617, Australia.ORCID 0000-0002-6422-7170
Gregory M PetersonSchool of Health Sciences, Faculty of Health, University of Canberra, Canberra 2617, Australia.ORCID 0000-0002-6764-3882
Israel Fernandez-CadenasStroke Pharmacogenomics and Genetics Group, Neurovascular Research Laboratory, Hospital de Sant Pau, 08041 Barcelona, Spain.
Reza MortazaviSchool of Health Sciences, Faculty of Health, University of Canberra, Canberra 2617, Australia.ORCID 0000-0001-8885-0891
University of Canberra · AUHospital de Sant Pau · ESUniversity of Tasmania · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntiplatelet medications such as aspirin and clopidogrel are used following thrombotic stroke or transient ischemic attack (TIA) to prevent a recurrent stroke. However, the antiplatelet treatments fail frequently, and patients experience recurrent stroke. One approach to lower the rates of recurrence may be the individualized antiplatelet therapies (antiplatelet therapy modification (ATM)) based on the results of platelet function analysis (PFA). This review was undertaken to gather and analyze the evidence about the effectiveness of such approaches.

methodsWe searched Medline, CINAHL, Embase, Web of Science, and Cochrane databases up to 7 January 2020.

resultsTwo observational studies involving 1136 patients were included. The overall effects of PFA-based ATM on recurrent strokes (odds ratio (OR) 1.05; 95% confidence interval (CI) 0.69 to 1.58), any bleeding risk (OR 1.39; 95% CI 0.92 to 2.10) or death hazard from any cause (OR 1.19; 95% CI 0.62 to 2.29) were not significantly different from the standard antiplatelet therapy without ATM.

conclusionsThe two studies showed opposite effects of PFA-guided ATM on the recurrent strokes in aspirin non-responders, leading to an insignificant difference in the subgroup meta-analysis (OR 1.59; 95% CI 0.07 to 33.77), while the rates of any bleeding events (OR 1.04; 95% CI 0.49 to 2.17) or death from any cause (OR 1.17; 95% CI 0.41 to 3.35) were not significantly different between aspirin non-responders with ATM and those without ATM. There is a need for large, randomized controlled trials which account for potential confounders such as ischemic stroke subtypes, technical variations in the testing protocols, patient adherence to therapy and pharmacogenetic differences.

Indexed as

antiplateletantiplatelet therapy modificationaspirinclopidogrelhigh on-treatment platelet reactivityischemic strokeplatelet function analysissecondary stroke preventionTIA

Identifiers

PMID33271959
PMCPMC7760730
OpenAlexW3098872687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.